The Effects of Cannabidiol Oil on Noninvasive Measures of Muscle Damage in Men

Cochrane-Snyman, Kristen C.; Cruz, Candelaria; Morales, Jacobo; Coles, Michael

doi:10.1249/mss.0000000000002606

Cited by 21 publications

(21 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite its growing popularity [ 16 ], only two interventional studies, both randomised, double-blind, placebo-controlled crossover trials, have so far investigated the effects of CBD on outcomes relevant to athletic performance. The first found no effect of CBD (150 mg·d −1 for 3 days) on non-invasive measures of muscle damage following eccentric exercise [ 19 ]. The second found CBD (60 mg; acute) decreased blood serum concentrations of creatine kinase and myoglobin, and increased one-repetition maximum back squat performance 72 h, but not 24 or 48 h following resistance exercise [ 20 ].…”

Section: Introductionmentioning

confidence: 99%

Effects of Cannabidiol on Exercise Physiology and Bioenergetics: A Randomised Controlled Pilot Trial

et al. 2022

View full text Add to dashboard Cite

Background Cannabidiol (CBD) has demonstrated anti-inflammatory, analgesic, anxiolytic and neuroprotective effects that have the potential to benefit athletes. This pilot study investigated the effects of acute, oral CBD treatment on physiological and psychological responses to aerobic exercise to determine its practical utility within the sporting context. Methods On two occasions, nine endurance-trained males (mean ± SD V̇O2max: 57.4 ± 4.0 mL·min−1·kg−1) ran for 60 min at a fixed intensity (70% V̇O2max) (RUN 1) before completing an incremental run to exhaustion (RUN 2). Participants received CBD (300 mg; oral) or placebo 1.5 h before exercise in a randomised, double-blind design. Respiratory gases (V̇O2), respiratory exchange ratio (RER), heart rate (HR), blood glucose (BG) and lactate (BL) concentrations, and ratings of perceived exertion (RPE) and pleasure–displeasure were measured at three timepoints (T1–3) during RUN 1. V̇O2max, RERmax, HRmax and time to exhaustion (TTE) were recorded during RUN 2. Venous blood was drawn at Baseline, Pre- and Post-RUN 1, Post-RUN 2 and 1 h Post-RUN 2. Data were synthesised using Cohen’s dz effect sizes and 85% confidence intervals (CIs). Effects were considered worthy of further investigation if the 85% CI included ± 0.5 but not zero. Results CBD appeared to increase V̇O2 (T2: + 38 ± 48 mL·min−1, dz: 0.25–1.35), ratings of pleasure (T1: + 0.7 ± 0.9, dz: 0.22–1.32; T2: + 0.8 ± 1.1, dz: 0.17–1.25) and BL (T2: + 3.3 ± 6.4 mmol·L−1, dz: > 0.00–1.03) during RUN 1 compared to placebo. No differences in HR, RPE, BG or RER were observed between treatments. CBD appeared to increase V̇O2max (+ 119 ± 206 mL·min−1, dz: 0.06–1.10) and RERmax (+ 0.04 ± 0.05 dz: 0.24–1.34) during RUN 2 compared to placebo. No differences in TTE or HRmax were observed between treatments. Exercise increased serum interleukin (IL)-6, IL-1β, tumour necrosis factor-α, lipopolysaccharide and myoglobin concentrations (i.e. Baseline vs. Post-RUN 1, Post-RUN 2 and/or 1-h Post-RUN 2, p’s < 0.05). However, the changes were small, making it difficult to reliably evaluate the effect of CBD, where an effect appeared to be present. Plasma concentrations of the endogenous cannabinoid, anandamide (AEA), increased Post-RUN 1 and Post-RUN 2, relative to Baseline and Pre-RUN 1 (p’s < 0.05). CBD appeared to reduce AEA concentrations Post-RUN 2, compared to placebo (− 0.95 ± 0.64 pmol·mL−1, dz: − 2.19, − 0.79). Conclusion CBD appears to alter some key physiological and psychological responses to aerobic exercise without impairing performance. Larger studies are required to confirm and better understand these preliminary findings. Trial Registration This investigation was approved by the Sydney Local Health District’s Human Research Ethics Committee (2020/ETH00226) and registered with the Australia and New Zealand Clinical Trials Registry (ACTRN12620000941965).

show abstract

Section: Introductionmentioning

confidence: 99%

Effects of Cannabidiol on Exercise Physiology and Bioenergetics: A Randomised Controlled Pilot Trial

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Improved sleep quality has been shown mainly in animal models [ 45 , 46 ] and not clearly in humans [ 47 , 48 , 49 ]. Additionally, first studies have shown a small effect on muscle soreness after CBD supplementation [ 50 , 51 ]. Concerning pro-regenerative effects of CBD in sport, currently only two studies exist which investigated biomarkers and performance parameters.…”

Section: Introductionmentioning

confidence: 99%

“…Concerning pro-regenerative effects of CBD in sport, currently only two studies exist which investigated biomarkers and performance parameters. In untrained males, the intake of CBD oil after six sets of ten maximal eccentric isokinetic elbow flexions did not result in any significant differences in perceived soreness, arm circumference, hanging joint angle, and peak torque between the groups [ 51 ]. In contrast, a pilot study [ 52 ] in highly trained men (>150% of body weight in the back squat [ 53 ]), showed an inhibitory effect of CBD on serum creatine kinase (CK) concentrations after three sets of 12 back squats at 70% 1RM plus three sets of 15 drop jumps landed in a deep squat.…”

Section: Introductionmentioning

confidence: 99%

Effects of Cannabidiol Supplementation on Skeletal Muscle Regeneration after Intensive Resistance Training

et al. 2021

View full text Add to dashboard Cite

Cannabidiol supplements (CBD) are increasingly consumed by athletes to improve regeneration. However, the evidence for the pro-regenerative effects of CBD in sports is quite limited. Therefore, our aim was to investigate the effects of a single CBD supplementation in a six-arm placebo-controlled crossover study after resistance training on performance and muscle damage. Before and after the resistance training, one-repetition maximum in the back squat (1RM BS), countermovement jump (CMJ), and blood serum concentrations of creatine kinase (CK) and myoglobin (Myo) were measured in healthy, well-trained participants. Sixteen of 21 participants completed the study and were included in the analysis. In 1RM BS, a significant decrease was observed after 24 h (p < 0.01) but not 48 or 72 h. A significant group difference was detected after 72 h (p < 0.05; ES = 0.371). In CMJ, no significant changes were observed. The CK and Myo concentrations increased significantly after 24 h (CK: p < 0.001; Myo: p < 0.01), 48 h (CK: p < 0.001; Myo: p < 0.01) and 72 h (CK: p < 0.001; Myo: p < 0.001). After 72 h, a significant group difference was observed in both muscle damage biomarkers (CK: p < 0.05 ES = 0.236; Myo: p < 0.05; ES = 0.214). The results show small and significant effects on muscle damage and recovery of squat performance after 72 h. However, more data are necessary for clearer statements about the pro-regenerative effects of CBD supplementation after resistance training.

show abstract

“…Additionally, nabiximols administration did meet several secondary endpoints associated with quality of life, which, as suggested by the authors, may indicate therapeutic utility in cancer pain as an adjuvant therapeutic with a low opioid dose ( Lichtman et al, 2018 ). In a small double-blinded, placebo-controlled, crossover design clinical study, oral CBD had no effect on muscle damage markers or muscle soreness in exercised untrained men ( Cochrane-Snyman et al, 2021 ). A recent double-blind, placebo controlled clinical study in an emergency room setting found that orally administered CBD was equal to placebo and did not adequately control acute non-traumatic low back pain ( Bebee et al, 2021 ).…”

Section: Cannabinoid Involvement In Central Nervous System Diseases A...mentioning

confidence: 99%

Medicinal Cannabis and Central Nervous System Disorders

2022

View full text Add to dashboard Cite

Cannabinoids, including those found in cannabis, have shown promise as potential therapeutics for numerous health issues, including pathological pain and diseases that produce an impact on neurological processing and function. Thus, cannabis use for medicinal purposes has become accepted by a growing majority. However, clinical trials yielding satisfactory endpoints and unequivocal proof that medicinal cannabis should be considered a frontline therapeutic for most examined central nervous system indications remains largely elusive. Although cannabis contains over 100 + compounds, most preclinical and clinical research with well-controlled dosing and delivery methods utilize the various formulations of Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), the two most abundant compounds in cannabis. These controlled dosing and delivery methods are in stark contrast to most clinical studies using whole plant cannabis products, as few clinical studies using whole plant cannabis profile the exact composition, including percentages of all compounds present within the studied product. This review will examine both preclinical and clinical evidence that supports or refutes the therapeutic utility of medicinal cannabis for the treatment of pathological pain, neurodegeneration, substance use disorders, as well as anxiety-related disorders. We will predominately focus on purified THC and CBD, as well as other compounds isolated from cannabis for the aforementioned reasons but will also include discussion over those studies where whole plant cannabis has been used. In this review we also consider the current challenges associated with the advancement of medicinal cannabis and its derived potential therapeutics into clinical applications.

show abstract

The Effects of Cannabidiol Oil on Noninvasive Measures of Muscle Damage in Men

Cited by 21 publications

References 57 publications

Effects of Cannabidiol on Exercise Physiology and Bioenergetics: A Randomised Controlled Pilot Trial

Effects of Cannabidiol on Exercise Physiology and Bioenergetics: A Randomised Controlled Pilot Trial

Effects of Cannabidiol Supplementation on Skeletal Muscle Regeneration after Intensive Resistance Training

Medicinal Cannabis and Central Nervous System Disorders

Contact Info

Product

Resources

About